MAXCYTE, INC. - 8-K Filing
MaxCyte reported Q1 2026 revenue of $9.7 million (down 7% YoY), with core revenue at $6.2 million (-25% YoY) and SPL Program-related revenue at $3.4 million (+62% YoY). The company reiterated full-year guidance for total revenue between $30-32 million, including $25-27 million in core revenue and ~$5 million from the SPL program. MaxCyte also announced a $10 million share repurchase authorization. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $MXCT